Your browser doesn't support javascript.
loading
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.
Kong, Tim; Laranjeira, Angelo B A; Collins, Taylor B; De Togni, Elisa S; Wong, Abigail J; Fulbright, Mary C; Ruzinova, Marianna; Celik, Hamza; Challen, Grant A; Fisher, Daniel A C; Oh, Stephen T.
Affiliation
  • Kong T; Division of Hematology, Department of Medicine.
  • Laranjeira ABA; Division of Hematology, Department of Medicine.
  • Collins TB; Division of Hematology, Department of Medicine.
  • De Togni ES; Division of Hematology, Department of Medicine.
  • Wong AJ; Division of Hematology, Department of Medicine.
  • Fulbright MC; Division of Hematology, Department of Medicine.
  • Ruzinova M; Department of Pathology and Immunology, and.
  • Celik H; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and.
  • Challen GA; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and.
  • Fisher DAC; Division of Hematology, Department of Medicine.
  • Oh ST; Division of Hematology, Department of Medicine.
Blood Adv ; 6(2): 611-623, 2022 01 25.
Article in En | MEDLINE | ID: mdl-34644371
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Primary Myelofibrosis / Myeloproliferative Disorders Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Primary Myelofibrosis / Myeloproliferative Disorders Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article Country of publication: